Kura Oncology Inc
KURA
Company Profile
Business description
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Contact
4930 Directors Place
Suite 500
San DiegoCA92121
USAT: +1 858 500-8800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
260
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,902.90 | 53.30 | -0.60% |
| CAC 40 | 8,123.41 | 31.50 | -0.39% |
| DAX 40 | 25,410.63 | 168.22 | -0.66% |
| Dow JONES (US) | 51,511.59 | 352.10 | -0.68% |
| FTSE 100 | 10,705.26 | 3.07 | -0.03% |
| HKSE | 24,766.82 | 67.30 | -0.27% |
| NASDAQ | 26,936.04 | 308.24 | -1.13% |
| Nikkei 225 | 65,883.41 | 864.46 | 1.33% |
| NZX 50 Index | 13,760.03 | 61.73 | -0.45% |
| S&P 500 | 7,706.03 | 58.61 | -0.75% |
| S&P/ASX 200 | 8,708.70 | 56.60 | -0.65% |
| SSE Composite Index | 3,909.95 | 26.57 | -0.68% |